Ask AI
Endo and Primary Care MASH Module

CE / CME

MASH Matters: New Evidence and Its Application to Endocrinology and Primary Care Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: August 01, 2025

Expiration: July 31, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 54-year-old patient with type 2 diabetes (T2D), obesity (BMI 33kg/m2), and well-controlled hypertension and hyperlipidemia presents for follow-up. Screening for viral hepatitis is negative. The patient does not consume alcohol.

According to current guidelines, what is the most appropriate next step in evaluating this patient?

2.

Which statement best characterizes semaglutide’s therapeutic potential in the management of MASH in patients with cardiometabolic risk factors according to the results of the phase III ESSENCE trial?

3.

How often do you currently work with a multidisciplinary team to improve the care of patients with MASLD/MASH?